TICKERNERD
Menu
CBLLCBLLHealthcare · Medical Devices

CBLL Stock Forecast: Ceribell, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$18
+3.50% on the day

The 8 Wall Street analysts covering Ceribell, Inc. hold a median 12-month price target of $26 — +42.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$671.2M
Ticker Nerd rank
28 / 100
Median analyst target
$26
Analysts covering
8
Total return, dividends reinvested
1W
+1.0%
1M
−6.3%
YTD
−16.5%
1Y
+29.5%
From 52W high
−21.9%
From 52W low
+67.7%
$11
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CBLL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ceribell, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
69
Revisions
58
Volatility
50
Size
49
Momentum
46
Value
40
Quality
33
Issuance
26
Growth
8

Accruals (69): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.

The rank is the raw material. Whether the rules would actually own Ceribell, Inc. — and when they’d sell — is the membership.

Wall Street

CBLL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CBLL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26CBLLHigh $32Median $26Low $24

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $24Median $26High $32

The green dot is the last close — the median target sits +42.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 May 2026Canaccord GenuityMaintainsBuy$28 → $25
12 May 2026Canaccord GenuityMaintainsBuy—
28 Jan 2026BTIGReiteratesBuy—
17 Dec 2025Canaccord GenuityMaintainsBuy—
15 Dec 2025BTIGReiteratesBuy—
5 Nov 2025JP MorganMaintainsOverweight—
5 Nov 2025TD CowenMaintainsBuy—
21 Oct 2025Raymond JamesInitiatesStrong Buy—
4 Apr 2025Ladenburg ThalmannInitiatesBuy—
26 Feb 2025Canaccord GenuityMaintainsBuy—
9 Dec 2024Canaccord GenuityMaintainsBuy—
9 Dec 2024TD CowenMaintainsBuy—
13 Nov 2024Canaccord GenuityMaintainsBuy—
5 Nov 2024B of A SecuritiesInitiatesBuy—
5 Nov 2024Canaccord GenuityInitiatesBuy—
5 Nov 2024JP MorganInitiatesOverweight—
5 Nov 2024TD CowenInitiatesBuy—
5 Nov 2024William BlairInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

CBLL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Ceribell, Inc. (CBLL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−12.4×

Cheaper than 94% of US stocks

Price / sales
7.2×

Cheaper than 18% of US stocks

Price / book
4.9×

Cheaper than 22% of US stocks

EV / EBITDA
−8.7×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
29.3%

Higher than 79% of US stocks

Earnings growth (YoY)
29.3%

Higher than 68% of US stocks

Gross margin
87.3%

Higher than 95% of US stocks

Operating margin
−78.3%

Higher than 15% of US stocks

Net margin
−63.5%

Higher than 8% of US stocks

Returns & dividend
Return on equity
−37.5%

Higher than 24% of US stocks

Return on assets
−20.7%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CBLL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CBLLCeribell, Inc.$671.2M
28
TCMDTactile Systems Technology, Inc.$635.4M
100
BBNXBeta Bionics, Inc.$564.8M
37
SSIISS Innovations International, Inc.$770.6M
22
SIBNSI-BONE, Inc.$784.4M
73
CTKBCytek Biosciences, Inc.$545.0M
60
KIDSOrthoPediatrics Corp.$506.3M
60
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CBLL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest CBLL news & analysis

Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System

GlobeNewsWire · 3 Aug 2026positive

Ceribell announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for its breakthrough point-of-care delirium monitor system. The company said the incremental NTAP reimbursement stands to broaden access to its first-of-its-kind platform for combined seizure and delirium monitoring.

Why it matters — A new CMS reimbursement pathway for one of Ceribell's monitoring products could broaden patient access and support adoption of the company's platform.

Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O'Keefe

GlobeNewsWire · 29 July 2026positive

Ceribell announced the appointments of Thomas West and Sharon O'Keefe to its Board of Directors, expanding the board as the company focuses on transforming diagnosis and management of serious neurological conditions.

Why it matters — Adding experienced leaders like West and O'Keefe to the board can bring valuable strategic guidance and industry expertise as Ceribell continues to grow.

Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference

GlobeNewsWire · 28 July 2026neutral

Ceribell announced that CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12, 2026.

Why it matters — The company's participation in a growth-focused investor conference signals an effort to increase visibility with the financial community.

FAQ

Frequently asked questions about CBLL stock

What is the CBLL stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Ceribell, Inc. have a median 12-month price target of $26, with estimates ranging from $24 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CBLL stock a buy right now?

Of the 8 analysts covering Ceribell, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ceribell, Inc. 28 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CBLL?

As at 1 Aug 2026, Ceribell, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (69 of 100).

Will CBLL stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +42.0% from the last close, and Ticker Nerd's factor model ranks Ceribell, Inc. 28 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CBLL stock forecast for 2030?

No analyst covering Ceribell, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CBLL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $32 over the next 12 months.

How has CBLL stock performed over the past year?

Ceribell, Inc. returned +29.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ceribell, Inc. do?

Ceribell, Inc. is a medical technology company specializing in AI-powered point-of-care electroencephalography systems for acute neurological care.

What is the latest news on CBLL?

The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System". Ceribell announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for its breakthrough point-of-care delirium monitor system. The company said the incremental NTAP reimbursement stands to broaden access to its first-of-its-kind platform for combined seizure and delirium monitoring.

Company

About Ceribell, Inc.

Ceribell, Inc. is a medical technology company specializing in AI-powered point-of-care electroencephalography systems for acute neurological care. The company’s core offering, the Ceribell System, is a rapidly deployable EEG platform designed for use in intensive care units, emergency departments, and other hospital settings where patients are at risk for seizures, status epilepticus, delirium, and other serious neurological conditions. Ceribell combines a disposable EEG headband, portable recording hardware, and bedside software with cloud connectivity and proprietary artificial intelligence algorithms to enable fast detection and continuous monitoring of suspected seizure activity. Its Clarity AI software supports real-time seizure-burden assessment at the bedside, helping clinicians triage patients more efficiently and integrate EEG into routine critical-care workflows. Ceribell operates today as a hybrid medical device and clinical software provider, focusing on neurodiagnostics and critical care monitoring across hospitals primarily in the United States. Founded in 2014 and headquartered in Sunnyvale, California, Ceribell plays a distinct role in the neurocritical care market by making EEG diagnostics more accessible, operationally efficient, and cost-effective at the point of care.

CEO Dr. Xingjuan Chao Ph.D. · 327 employees · United States · https://www.ceribell.com